Research - onset.to

January 3, 2027

UK petition calls for a legal review of psilocybin access and policy, asking Parliament to consider reform for medical use, research, and reduced criminal penalties

petition.parliament.uk · Jan 3, 2027

Psilocybin Mainstream Policy Research

November 5, 2026

Waves and Stones: Graham Harman explores how continuity and sudden change shape reality, science, history, and human life

penguin.co.uk · Nov 5, 2026 · Graham Harman

Article Consciousness Philosophy Research

Yesterday October 6, 2026

Cannabinoids may intensify anxiety by releasing a neural brake in the brain's fear center during stress

sciencedaily.com · Oct 6, 2026

Cannabis Article Clinical Research Safety

October 5, 2026

Psyence signs a US ibogaine manufacturer, but DEA approvals, import limits, quotas, and clinical filings remain unresolved

behavioralwire.com · Oct 5, 2026 · Editorial Desk

Ibogaine Article Industry Policy Research

Podcast: Oregon abandons psilocybin fee hike as California funds research and DEA again moves to schedule five tryptamines

psychedelicalpha.com · Oct 5, 2026 · Josh Hardman

Psilocybin Podcast Industry Policy Research

Robert Rush challenges the DEA’s evidence and proposed Schedule I classification of five tryptamines

divergentstates.buzzsprout.com · Oct 5, 2026

Podcast Ethics Policy Research

September 30, 2026

Higher resilience linked to more intense challenging ayahuasca experiences and stronger meaning-seeking afterward

psypost.org · Sep 30, 2026 · Vladimir Hedrih

Ayahuasca Article Clinical Integration Research

DEA proposes Schedule I status for five tryptamines as Oregon drops psilocybin fee hikes and GAO questions scheduling procedures

psychedelicstoday.com · Sep 30, 2026 · Jack Gorsline

Psilocybin Article Industry Policy Research

Eine einzelne MDMA-Dosis verhindert bei genetisch besonders gefährdeten Ratten einen traumabedingten Anstieg des Alkoholkonsums

psypost.org · Sep 30, 2026 · Eric W. Dolan

MDMA Article Clinical Research Safety DE

September 29, 2026

MAPS opposes the DEA's attempt to place five lesser-known tryptamines into Schedule I under the Controlled Substances Act

maps.org · Sep 29, 2026 · Ismail L. Ali, J.D.

Article Policy Research Safety

September 28, 2026

Psychedelics reduce bottom-up brain activity in the default mode network across humans and mice

psypost.org · Sep 28, 2026 · Karina Petrova

LSD Psilocybin Article Clinical +2

September 27, 2026

Exploratory clinical trial finds ayahuasca combined with meaning reconstruction therapy may ease severe bereavement

psypost.org · Sep 27, 2026 · Karina Petrova

Ayahuasca Article Clinical Research Therapy

September 25, 2026

Scientists identify the LSD structural elements that trigger hallucinations and create a promising non-hallucinogenic antipsychotic analogue

psypost.org · Sep 25, 2026 · Eric W. Dolan

LSD Article Clinical Research Safety

September 24, 2026

Draulio Araújo on the path from ayahuasca research to controlled DMT trials for treatment-resistant depression

behavioralwire.com · Sep 24, 2026 · Editorial Desk

DMT Ayahuasca Article Clinical +2

Psilocybin durably increases sociability in an autism mouse model even when administered under anesthesia

psypost.org · Sep 24, 2026 · Eric W. Dolan

Psilocybin Article Clinical Research Safety

A Single Supported Psilocybin Session Was Linked to Months of Reduced Cancer-Related Anxiety and Depression

mindbodygreen.com · Sep 24, 2026

Psilocybin Article Clinical Research Therapy

September 23, 2026

First fMRI study of mescaline in awake rats finds reduced cerebellar activity, increased brain connectivity, and frequency-specific sensory filtering

psypost.org · Sep 23, 2026 · Bianca Setionago

Mescaline Article Consciousness Research Safety

A Phase 1 trial tests psilocybin for borderline personality disorder while keeping dialectical behavior therapy in place

behavioralwire.com · Sep 23, 2026 · Editorial Desk

Psilocybin Article Clinical Research Safety

DEA proposes Schedule I classification for five synthetic tryptamine psychedelics, threatening research and clinical development

mindmedicinelaw.com · Sep 23, 2026 · The Psychedelic Journal

Article Policy Research Safety

DEA renews effort to place five psychedelic tryptamines in Schedule I as FDA research progress draws criticism from advocates

psychedelicamericas.org · Sep 23, 2026 · PSA Media Team, Jack Gorsline

Article Industry Policy Research

September 22, 2026

Psilocybin may help the brain recover from repeated concussion, but evidence remains limited to animal research

theconversation.com · Sep 22, 2026 · Argel Aguilar Valles

Psilocybin Article Clinical Research Safety

FDA hearing, VA psychedelic bill claims, and Alabama's marijuana rescheduling objection shape September 2026 policy briefing

psychedelicstoday.com · Sep 22, 2026 · Jack Gorsline

Psilocybin MDMA Article Industry +2

After an Ayahuasca Retreat: Research-Based Answers to Questions About Integration, Difficulties, Grounding, Community and Help

hummingbirdhealingcenter.org · Sep 22, 2026 · Jim Davis

Psilocybin Ayahuasca Article Integration +2

Psychedelic realism with Danny Forde: phenomenology, mystical experience, ego dissolution, and the search for truth

divergentstates.buzzsprout.com · Sep 22, 2026

Podcast Consciousness Philosophy Research

September 21, 2026

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

psychedelicalpha.com · Sep 21, 2026 · Josh Hardman

Ibogaine MDMA Podcast Industry +2